Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Plus Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT05179317Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Qilu Pharmaceutical. Primary endpoint: Number of Participants Who Experienced At Least One Adverse Event. Status: unknown.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05179317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179317.